Literature DB >> 18395047

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Chunhua Lu1, Premal H Thaker, Yvonne G Lin, Whitney Spannuth, Charles N Landen, William M Merritt, Nicholas B Jennings, Robert R Langley, David M Gershenson, George D Yancopoulos, Lee M Ellis, Robert B Jaffe, Robert L Coleman, Anil K Sood.   

Abstract

OBJECTIVE: The purpose of this study was to examine the functional and therapeutic significance of pericytes in ovarian cancer vasculature. STUDY
DESIGN: Tumor vessel morphologic condition and efficacy of endothelial and pericyte targeting were examined with the use of in vivo ovarian cancer models. The expression of platelet-derived growth factor (PDGF) ligands and receptors was examined in endothelial, pericyte-like, and ovarian cancer cells.
RESULTS: Relative to normal vessels, tumor vasculature was characterized by loosely attached pericytes in reduced density. PDGF-BB was expressed predominantly by the endothelial and cancer cells, whereas PDGFRbeta was present in pericyte-like cells. PDGF-BB significantly increased the migration of and VEGF production by pericyte-like cells; PDGFRbeta blockade abrogated these effects. Dual VEGF (VEGF-Trap) and PDGF-B (PDGF-Trap) targeted therapy was more effective in inhibiting in vivo tumor growth than either agent alone.
CONCLUSION: Aberrations in the tumor microenvironment contribute to endothelial cell survival. Strategies that target both endothelial cells and pericytes should be considered for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395047      PMCID: PMC2346589          DOI: 10.1016/j.ajog.2007.12.028

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  35 in total

1.  Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival.

Authors:  N Reinmuth; W Liu; Y D Jung; S A Ahmad; R M Shaheen; F Fan; C D Bucana; G McMahon; G E Gallick; L M Ellis
Journal:  FASEB J       Date:  2001-05       Impact factor: 5.191

Review 2.  Developmental roles of platelet-derived growth factors.

Authors:  C Betsholtz; L Karlsson; P Lindahl
Journal:  Bioessays       Date:  2001-06       Impact factor: 4.345

3.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors:  P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  Molecular determinants of ovarian cancer plasticity.

Authors:  A K Sood; E A Seftor; M S Fletcher; L M Gardner; P M Heidger; R E Buller; R E Seftor; M J Hendrix
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.

Authors:  Brian C Cooper; Justine M Ritchie; Carrie L W Broghammer; Jeremy Coffin; Joel I Sorosky; Richard E Buller; Mary J C Hendrix; Anil K Sood
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

6.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 7.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

8.  Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis.

Authors:  Robert R Langley; Karen M Ramirez; Rachel Z Tsan; Melissa Van Arsdall; Monique B Nilsson; Isaiah J Fidler
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

9.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

10.  Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis.

Authors:  M Hellström; H Gerhardt; M Kalén; X Li; U Eriksson; H Wolburg; C Betsholtz
Journal:  J Cell Biol       Date:  2001-04-30       Impact factor: 10.539

View more
  21 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

Review 2.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

3.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

4.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

5.  Regulation of tumor angiogenesis by EZH2.

Authors:  Chunhua Lu; Hee Dong Han; Lingegowda S Mangala; Rouba Ali-Fehmi; Christopher S Newton; Laurent Ozbun; Guillermo N Armaiz-Pena; Wei Hu; Rebecca L Stone; Adnan Munkarah; Murali K Ravoori; Mian M K Shahzad; Jeong-Won Lee; Edna Mora; Robert R Langley; Amy R Carroll; Koji Matsuo; Whitney A Spannuth; Rosemarie Schmandt; Nicholas B Jennings; Blake W Goodman; Robert B Jaffe; Alpa M Nick; Hye Sun Kim; Eylem Ozturk Guven; Ya-Huey Chen; Long-Yuan Li; Ming-Chuan Hsu; Robert L Coleman; George A Calin; Emir B Denkbas; Jae Yun Lim; Ju-Seog Lee; Vikas Kundra; Michael J Birrer; Mien-Chie Hung; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

Review 6.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Authors:  Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

7.  Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression.

Authors:  Marcela Franco; Pernilla Roswall; Eliane Cortez; Douglas Hanahan; Kristian Pietras
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

8.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

Review 9.  Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.

Authors:  Justin N Bottsford-Miller; Robert L Coleman; Anil K Sood
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

10.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.